I own PSTI but rarely post anymore
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It was Covanta who choose to test GEYI - Alphakat KDV 500 after looking at over 200 other companies over a two year time. You keep touting the JBII LOI but so far I have not seen JBII getting a multi billion dollar company interested and even if they do, how long do you think they will want to test a JBI system?
Double standard DD? Go ahead and tear into this little company all you want as I am not a daytrader and I will not be around all the time to correct misinformation and I would not mind buying some more shares cheaper so hopefully you can shake out some weak hands. MOMO does not matter here as I expect the stock to move up on good news. Thanks
GEYI's potential partner Covanta is on top of the list of fastest growing environmental stocks...
http://www.cnanalyst.com/2011/04/top-10-fastest-growing-environmental-stocks-cva-dgw-ades-ntic-ve-smed-hcci-pmfg-prmw-ftek-apr-27-201.html
Top 10 Fastest-Growing Environmental Stocks: CVA, DGW, ADES, NTIC, VE, SMED, HCCI, PMFG, PRMW, FTEK (Apr 27, 2011)
Best-Rated Chinese Stocks; Highest-Upside; Fastest-Growing; Top 10 Lists; Analyst Actions
Below are the top 10 fastest-growing Environmental stocks, UPDATED TODAY before 4:30 AM ET, based on the average long-term earnings growth rate estimated by Wall Street analysts. One Chinese company (DGW) is on the list.
Covanta Holding Corporation (NYSE:CVA) is the 1st fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 61.6%. This number is based on the average estimate of 1 brokerage analysts. Duoyuan Global Water Inc (ADR) (NYSE:DGW) is the 2nd fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 55.4%. This number is based on the average estimate of 1 brokerage analysts. ADA-ES, Inc. (NASDAQ:ADES) is the 3rd fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 50.0%. This number is based on the average estimate of 1 brokerage analysts. Northern Technologies International Corp (NASDAQ:NTIC) is the 4th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 26.5%. This number is based on the average estimate of 2 brokerage analysts. Veolia Environnement (ADR) (NYSE:VE) is the 5th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 26.0%. This number is based on the average estimate of 1 brokerage analysts.
Sharps Compliance Corp. (NASDAQ:SMED) is the 6th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 25.0%. This number is based on the average estimate of 2 brokerage analysts. Heritage-Crystal Clean, Inc. (NASDAQ:HCCI) is the 7th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 25.0%. This number is based on the average estimate of 1 brokerage analysts. PMFG Inc (NASDAQ:PMFG) is the 8th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 25.0%. This number is based on the average estimate of 1 brokerage analysts. Primo Water Corporation (NASDAQ:PRMW) is the 9th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 25.0%. This number is based on the average estimate of 1 brokerage analysts. Fuel Tech Inc. (NASDAQ:FTEK) is the 10th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 20.0%. This number is based on the average estimate of 2 brokerage analysts.
SUBSCRIBE TO OUR FREE DAILY EMAIL UPDATES
DAILY STOCK RANKINGS
* Earnings-Doubling Stocks in Next 5 Years (Apr 28,...
* Daily Top-10 Stock Rankings (Apr 28, 2011)
* Top Canadian Stocks with Highest Upside Potential...
* Daily U.S. Market Headlines (Apr 28, 2011)
* Top Rising Stocks with Unusual Volume (Apr 28, 2011)
* Top Falling Stocks with Unusual Volume (Apr 28, 2011)
* Latest 52-Week Low Stocks (Apr 28, 2011)
* Latest 52-Week High Stocks (Apr 28, 2011)
* Best-Rated Large Cap Stocks (Apr 27, 2011)
* Daily Top-10 Stock Rankings (Apr 27, 2011)
* Best-Rated Micro Cap Stocks (Apr 27, 2011)
* Best-Rated Mid-Cap Stocks (Apr 27, 2011)
* Daily U.S. Market Headlines (Apr 27, 2011)
* Best-Rated Small Cap Stocks (Apr 27, 2011)
* Top Falling Stocks with Unusual Volume (Apr 27, 2011)
* Latest 52-Week Low Stocks (Apr 27, 2011)
* Fastest-Growing Canadian Stocks (Apr 27, 2011)
* Fastest-Growing U.K. Stocks (Apr 27, 2011)
* Latest 52-Week High Stocks (Apr 27, 2011)
* Top Rising Stocks with Unusual Volume (Apr 27, 2011)
* Daily Top-10 Stock Rankings (Apr 26, 2011)
* Daily U.S. Market Headlines (Apr 26, 2011)
* Top Falling Stocks with Unusual Volume (Apr 26, 2011)
* Best-Performing Canadian Stocks Year-to-Date (Apr...
* Best-Performing U.K. Stocks Year-to-Date (Apr 26,...
View all »
RELATED ARTICLES
* Analyst Actions on Chinese Stocks: BIDU, CEA, CEO,...
* Top U.S.-Listed Chinese Stocks with Highest Momentum...
* Daily News and Research on Chinese Stocks (Apr 28,...
* Top 10 Specialty Finance Stocks with Highest Short...
* Top 10 Solar Stocks with Highest Short Interest: SPWRA,...
* Top 10 Fastest-Growing Large Cap Stocks: BIDU, CXO,...
* Top 10 Fastest-Growing Mid-Cap Stocks: UTHR, TXT,...
* Top 10 Fastest-Growing Small Cap Stocks: DANG, AONE,...
* Top 10 Fastest-Growing Micro Cap Stocks: CKSW, CVVT,...
* Top 10 Focus Stocks of The Day: RLOC, REGN, CLUB,...
View all »
Well, you had better hope that JBI Global does not infringe on GEYI-AlphaKAT, Lubrizol or anyone else's patents as that would be game over for investors (shown as one of the concerns in the JBII SEC filings). Good luck getting the whales to bite on that one (where one patent infringement lawsuit could potentially wipe out the whole company) JMHO
GEYI closed at $.045 & JBII closed at $2.25 today - BTW, nice promo-momo going on over there.
Lets revisit this post in 6 months and see how they compare then. I can accept being wrong as this is just a speculation play for me but if Covanta orders the 600 units as previously stated, I think GEYI will be the percentage winner JMHO.
They added a new Director who actually put $500,000 cash into GEYI common stock which is unlike most directors (even some JBII directors) that are just given stock for free. Insiders have also been buying out the YA toxic financing, again it is insiders buying and they have bought a lot more at much higher levels.
Not saying that there is not risk here but the recent activities of GEYI insiders and Covanta offering to pay more for expanded rights to the Alphakat system are looking good to me, JMHO.
It has been operating at the Covanta Massachusetts plant since June 2010 and the Alphakat system does not have any stack to test which is one of the reasons the Army is interested as they can recycle all organic waste (not just the plastic) and not be concerned about stack pollution wherever in the world they need it to go...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61957977
Covanta - GEYI stated up front that it would take 6 months to a year to fully test the system.
Well, you had better hope that JBI Global does not infringe on GEYI - AlphaKAT, Lubrizol or anyone else's patents as that would be game over for investors (shown as one of the concerns in the JBII SEC filings). Good luck getting the whales to bite on that one (where one patent infringement lawsuit could wipe out the whole company).
Resorting to name calling shows a certain level of desperation and denial but I am comfortable with my DD on JBII competitor GEYI regardless of your distorted opinions. I understand the risks but I believe Covanta and the Army cannot be as easily fooled as a few message board posters.
Investor Alert: Pluristem’s PLX Cells could be used for the Prevention and Treatment of Radiation Exposure April 28, 2011 by Ray Dirks
Pluristem’s PLX Cells could be used for the Prevention and Treatment of Radiation
April 28, 2011
By Ray Dirks
In following up Pluristem’s press release on April 6, 2011, I attended a presentation by Pluristem’s CEO Zami Aberman. I left that meeting believing that Pluristem’s PLX cells could not only treat the adverse bone-marrow related effects of radiation exposure but potentially prevent those effects from happening in the first place. For example, if a population of people who had been exposed to radiation (such as what recently happened in Japan) receives PLX cells promptly after exposure, patients could potentially be protected from illnesses such as leukemia, which is known to occur as a long term side effect of radiation exposure. Additionally, for that population exposed but unable receive PLX cells shortly after exposure, they could receive PLX cells later to help reconstitute their bone marrow. This belief is, in part, based on research the company has already completed that indicated that animals subjected to radiation and the, injected with PLX cells had a significant recovery of bone marrow. Additionally, the Company also found that PLX cells are cytoprotective and could protect the bone marrow from being harmed after exposure. The Company will also initiate studies to see if PLX cells can prevent the near-term symptoms of radiation sickness, like the GI side effects of Nausea, vomiting, diarrhea, ect.
Ray Dirks Research could reasonably see where societies would want to stockpile Cryopreserved PLX cells, maybe even while continued research is conducted on PLX cells for this indication.
In yesterday’s article published on Seeking alpha by Jason Napodano entitled “ Competition Between Aastrom Bio and Pluristem Heating Up” he makes a totally irrelevant point, Pluristem and Aastrom are not comparable. Aastrom’s is pursuing an autologous, bone marrow-derived cell therapy strategy and therefore, by definition, has to pursue a business strategy of personalized medicine. Pluristem is pursuing an allogeneic, placental-derived cell therapy strategy that is intended to supply cells to the general population as an “off-the-shelf” product in as close a manner as possible as tablets and capsules are supplied today. We hope Aastrom is successful with their strategy as it will help validate to the market that cell therapy works and is here to stay.
I pointed out in my report dated March 8, 2011 the value discrepancy between Pluristem and Mesoblast, which is considered a comparable company. And see our full report issued on Jan 24, 2011 also available on CPReports.com, Reports Blog section. To contact Ray directly email rdirks@nyc.rr.com
Watch the diesel directly from the KDV get poured into a car that has ran over 100,000 miles so not sure where your dog poop comes from?
“During the past two years, we have looked at more than 200 waste conversion technologies and we believe this technology warrants further testing as part of our efforts to develop clean, renewable energy solutions,” said Covanta VP-business development Steven Weber.
“If successful, this technology will complement our core Energy from Waste business, extending the line of products and services which we offer customers to provide clean, renewable energy.”
As Weber explained in an interview with Hart Energy Publishing, the pilot project aims to produce U.S. EPA-quality highway diesel fuel.
That means meeting EPA’s 15-ppm sulfur limit for highway ultra-low sulfur diesel (ULSD) fuel. If testing shows that extra desulfurization equipment would need to be added following the catalytic conversion of RDF, then a special module would be added, Weber explained to us.
Covanta decided the technology warranted a closer look given the enormous amount of trash that is land-filled in the U.S. every year – some 250 million tons.
Even if more aggressive recycling and re-use schemes were to cut the amount of U.S. trash available for conversion by half, the energy-production potential would still be significant, he said.
Given that Covanta already has air and waste permits for its existing RDF power-plant facility – and given that the diesel demonstration plant would only yield a slight amount of incremental air emissions – environmental permitting for the project is less challenging than at other locations, Weber pointed out. Effectively, incremental emissions would be “offset by the benefit of net reductions in greenhouse gas emissions,” he explained.
If the demonstration proves successful, then Covanta aims to obtain EPA registration for the diesel fuel.
Asked about production cost, Weber said: “This has great potential, but we still have many hurdles to clear before we will know if it is commercially viable.”
If studies show the fuel can indeed be economically competitive, and if the process proves itself as robust – with high plant availability – then “we’re looking at a commercial roll-out at both our existing plants and greenfield projects,” he said.
Such plants potentially could tap a variety of feeds beyond MSW, including waste-oils, biomass, construction & demolition waste, logging residues, yard waste and “just about anything with hydrogen and carbon in it,” he said.
Eventually, that might include purpose-grown, non-food energy crops such as switchgrass, jatropha, or byproducts such as corn stover, he pointed out. – Jack Peckham
–Jack Peckham
excerpt from:
http://www.worldfuels.com/wfExtract/exports/Content/8a486955-9d14-410d-944e-cc06be5f2fd2.html
______________________________
Note: It took over 2 years before Covanta selected Alphakat - GEYI and it has been over 3 years since then even while the process continues to advance which just goes to show that it is a very time consuming process to get the "big boys" to look at and test a revolutionary new system.
http://siliconinvestor.advfn.com/readmsg.aspx?msgid=27335442
At your request, competitor GEYI filings...
http://secwatch.com/geyi
This is the company that has the exclusive rights to Alphakat in the US. Alphakat disassociated themselves with the company of ill repute before aligning themselves with GEYI.
Covanta studied over 200 systems before choosing GEYI- Alphakat and have been testing it in the USA since June 2010 (and they stated up front it would take 6 months to a year to complete the testing).
The Alphakat KDV 500 does not have a stack so no stack test.
That information is older than Kidd's shares and you listed the WRONG website for JBII competitor GEYI (who's CEO used to be the Director General of the Israel Minister of Energy & Infrastructure).
http://www.global-nrg.biz/it_works.html
"Asi Shalgi (CEO) a seasoned manager with over 20 years' experience in the energy sector at the highest level. Asi served as the Director General of the Israel Ministry of Energy & Infrastructure and as a director or CEO of several industrial and agriculture companies. He has been involved several energy related projects, including the development, building and operation of the first private power plant and the first private water desalination plant in Israel."
Covanta is the WTE giant in the USA and they took 2 years and looked at over 200 systems before choosing the Alphakat-GEYI modular system and it has been fully operational in the USA since June 2010 (PS it does not even have a stack).
If you want to overlook everything that John Bordynuik has said...
http://siliconinvestor.advfn.com/readmsg.aspx?msgid=27285908
then that is up to you but I must protest when you give false information on competitor GEYI.
Mesoblast Limited (ASX:MSB) Included In Standard And Poor/ASX 200 Index
Press Release Source: ABN Newswire On Monday 18 April 2011, 9:21 EST
Melbourne, Australia, April 18, 2011 - (ABN Newswire) - Standard and Poor's (S&P) Indices has announced that regenerative medicine company Mesoblast Limited (ASX:MSB.AX) (Other OTC:MBLTY.PK) will be included in the S&P/ASX 200 Index, effective after the close of business on Wednesday 27 April, 2011.
"Inclusion in the S&P/ASX 200 index is a major achievement for Mesoblast," said Chief Executive Professor Silviu Itescu. "This important milestone serves to further underscore the company's strong financial performance and global leadership in the field of regenerative medicine."
About S&P/ASX 200
The S&P/ASX 200 is recognized as the primary investable benchmark in Australia. The index covers approximately 78% of Australian equity market capitalization. Index constituents are drawn from eligible companies listed on the Australian Securities Exchange. This index is designed to address investment managers' needs to benchmark against a portfolio characterized by sufficient size and liquidity.
About S&P Indices
S&P Indices, the world's leading index provider, maintains a wide variety of investable and benchmark indices to meet an array of investor needs. Over $1.25 trillion is directly indexed to Standard & Poor's family of indices.
About Mesoblast Limited:
Mesoblast Limited (ASX:MSB.AX) (Other OTC:MBLTY.PK) is a world leader in commercializing biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.com
Contact:
Julie Meldrum
Corporate Communications Director
T: +61-3-9639-6036
C: +61-419-228-128
Email:julie.meldrum@mesoblast.com
Source:
Mesoblast Limited
Copyright (C) 2011 ABN Newswire. All rights reserved.
http://au.finance.yahoo.com/news/Mesoblast-Limited-ASX-MSB-asiacorp-341566014.html?x=0&.v=1
Mesoblast Limited (ASX:MSB) Included In Standard And Poor/ASX 200 Index
Press Release Source: ABN Newswire On Monday 18 April 2011, 9:21 EST
Melbourne, Australia, April 18, 2011 - (ABN Newswire) - Standard and Poor's (S&P) Indices has announced that regenerative medicine company Mesoblast Limited (ASX:MSB.AX) (Other OTC:MBLTY.PK) will be included in the S&P/ASX 200 Index, effective after the close of business on Wednesday 27 April, 2011.
"Inclusion in the S&P/ASX 200 index is a major achievement for Mesoblast," said Chief Executive Professor Silviu Itescu. "This important milestone serves to further underscore the company's strong financial performance and global leadership in the field of regenerative medicine."
About S&P/ASX 200
The S&P/ASX 200 is recognized as the primary investable benchmark in Australia. The index covers approximately 78% of Australian equity market capitalization. Index constituents are drawn from eligible companies listed on the Australian Securities Exchange. This index is designed to address investment managers' needs to benchmark against a portfolio characterized by sufficient size and liquidity.
About S&P Indices
S&P Indices, the world's leading index provider, maintains a wide variety of investable and benchmark indices to meet an array of investor needs. Over $1.25 trillion is directly indexed to Standard & Poor's family of indices.
About Mesoblast Limited:
Mesoblast Limited (ASX:MSB.AX) (Other OTC:MBLTY.PK) is a world leader in commercializing biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.com
Contact:
Julie Meldrum
Corporate Communications Director
T: +61-3-9639-6036
C: +61-419-228-128
Email:julie.meldrum@mesoblast.com
Source:
Mesoblast Limited
Copyright (C) 2011 ABN Newswire. All rights reserved.
http://au.finance.yahoo.com/news/Mesoblast-Limited-ASX-MSB-asiacorp-341566014.html?x=0&.v=1
It looks like something is up.
New Pick GEYI $.045
Speculative buy (thinking that the recent signals indicate to me that the Covanta deal is looking good).
As soon as I can get another pick I would like to add GEYI.
Updates to my previous post...
APNT - Load the boat and trade the channel if you are so inclined but this should only get better over time. IMHO
BLTI - New 52 week high - Monster!!!
NNVC - Load the boat and trade the channel if you are so inclined but this should only get better over time. IMHO
PSTI - Look at my previous post here where I called it at $2.39 and it is now $3 and I expect at LEAST a 3x - 7x over the next year JMHO. To be honest, I have been in the stock since under $2 averaging up and I have called it a screaming buy up to the last shelf price of $3.25. If you want the mega lotto play, you can even get Sept options on PSTI.
BCTE - Looks like the bad news is behind us and I don't see much downside and upside could be spectacular in a quarter or two, plus it is a natural gas play with an environmental green side.
MTRE - after being a no-brainer for almost a year up (50-100 percent) some large holders have given up on it and I really do not know what to think. I hope everyone took advantage of the peaks and are holding free shares.
HDVY - see my recent post on that board for my current thoughts.
GEYI - see these post...
http://siliconinvestor.advfn.com/readmsg.aspx?msgid=27304479
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61963542
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=60727014
Taking another look at HDVY and the recent changes with cut-backs and more people leaving has caused me to reconsider my position. If they get a deal with a big lab company, yes it will be huge (and I hope they do but not liking the recent signals). Problem is, they may never tell you if all the deals fail because they do not want a race to the exit and they like their paycheck. So slow and continual decline similar to what we are seeing would be the norm. If insiders were buying heavy, I would probably change my mind.
Story stocks are a dime a dozen and I have picked some real winners and losers, so I like to step back once in a while and start fresh looking at my stocks as if I were thinking of buying for the first time and ask myself is the current risk worth the reward compared to other story stocks. JMHO
NI Technology Updates Outlooks for Microsoft, Nokia, Intel, ARM Holdings, and MIPS Technology
Arm Holdings, Plc ADS Each Representing 3 Ordinary Shares (MM) (NASDAQ:ARMH)
Today : Friday 15 April 2011
Next Inning Technology Research (http://www.nextinning.com), an online investment newsletter focused on semiconductor and technology stocks, has updated outlooks for Microsoft (Nasdaq: MSFT), Nokia (NYSE: NOK), Intel (Nasdaq: INTC), ARM Holdings (Nasdaq: ARMH), and MIPS Technology (Nasdaq: MIPS).
Next Inning editor Paul McWilliams has leveraged a decades-long career as a semiconductor industry insider to deliver in-depth insights and winning stock selections for his newsletter subscribers. McWilliams' Next Inning model portfolio is approaching the "five-bagger" level, returning nearly 340% since its inception in 2002, and he has been picking more potential big winners for 2011.
Steven Halpern, the editor of The Stock Advisors report, which tracks 75 subscription newsletters and publishes the AOL Top Picks Report, had this to say about McWilliams:
"I have followed the financial newsletter industry for 28 years, reading hundreds of financial advisors. Without doubt, Paul McWilliams offers among the most in-depth, highest quality and well-reasoned research available in the marketplace. I've rarely ever seen an advisor who is as knowledgeable -- and accurate -- regarding the sectors and stocks that they follow."
Trial subscribers will also receive McWilliams' highly acclaimed State of Tech series, offering in-depth, sector-by-sector coverage of over 65 leading tech companies. The full set of State of Tech reports will be published ahead of earnings season, offering specific guidance on which stocks he thinks investors should own and which should be avoided.
To take advantage of this offer and receive these reports for free, please visit the following link:
https://www.nextinning.com/subscribe/index.php?refer=prn1201
McWilliams covers these topics and more in his recent reports:
-- What is Wall Street getting wrong about the Intel story? We've all read the headline news about Intel, but to get the real inside story about what Intel is doing you need to get it from an industry insider. In his special Intel State of Tech report McWilliams explains in clear layman's terms where Intel, ARM Holdings, and MIPS will fit in with the rapidly evolving smartphone and tablet markets and how cloud computing will impact personal computing. In addition to these unique perspectives on Intel, ARM, and MIPS, you will also see the details behind McWilliams' fair value model for Intel as well as his predictions for both Intel's Q1 performance and Q2 guidance. Industry experts rank this as an eye-opening and must-read report for semiconductor investors.
-- What does McWilliams mean when he writes, "Intel is coming at the smartphone sector from the polar opposite direction of ARM Holdings." When looking at mobile markets, where are Intel and MIPS still playing catch up to ARM, and where are they making inroads against ARM's "first mover" advantages?
-- Does McWilliams have bullish view of Microsoft based on Windows 7, Kinect, and its mobile strategy? Might an investment in Nokia be a better way to profit from Microsoft's mobile strategy than investing in Microsoft itself? Is Nokia a turnaround story in the making?
Founded in September 2002, Next Inning's model portfolio has returned 336% since its inception versus 45% for the S&P 500.
About Next Inning:
Next Inning is a subscription-based investment newsletter that provides regular coverage on more than 150 technology and semiconductor stocks. Subscribers receive intra-day analysis, commentary and recommendations, as well as access to monthly semiconductor sales analysis, regular Special Reports, and the Next Inning model portfolio. Editor Paul McWilliams is a 30+ year semiconductor industry veteran.
NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926. Interested parties may visit adviserinfo.sec.gov for additional information. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
CONTACT: Marcia Martin, Next Inning Technology Research, +1-888-278-5515
SOURCE Indie Research Advisors, LLC
Another 52 week high !!!
On your shorts of NNVC... I have not ever shorted a stock (So far) and I generally do limited trading so my question is: if your broker has shares and you borrow them what happens if the borrowed shares are sold and no more shares are available? Can the broker call in your short shares forcing cover or is it your brokers problem to find shares elsewhere?
I still think there would be much better candidates for shorting than NNVC with the high number of short shares and the potential for quick and huge news, BWDIK.
Nice news :) for my largest holding!!!
Echo Therapeutics Announces Patent for Symphony™ tCGM System
Echo Therapeutics (OTCBB:ECTE)
Today : Tuesday 12 April 2011
FRANKLIN, Mass., April 12, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that it received a notice of allowance for U.S. Patent Application No.11/275,038, "System and Method for Continuous Non-Invasive Glucose Monitoring," for the Symphony tCGM System.
The patent, describing the method of use for the Symphony tCGM System in the hospital critical care setting, has been allowed in the United States and is expected to issue in the next few months. The patent will expire in December 2025.
"Building on our positive fundamentals, we are excited to be issued this notice of allowance for a key component of our intellectual property portfolio," stated Patrick Mooney, M.D., Echo's Chairman and CEO. "This patent is critical to our intellectual property strategy for protecting our leading position in non-invasive, tCGM markets worldwide. Furthermore, we expect several additional patents to issue this year worldwide for both our Prelude SkinPrep System and our Symphony System as we build a solid foundation for future growth. We expect these patents will add significantly to our shareholder value in both the near- and long-term."
The patent application describes the continuous monitoring of glucose in a critical care environment. It describes a device that graphs a patient's glucose over time, provides for hypo- and hyperglycemic alarms, displays the glucose trend/rate of change, and allows set points for insulin delivery. The application also describes a miniature transdermal glucose sensor, is affixed over an area of permeated skin, that transmits to the monitor. The Symphony tCGM System incorporates Echo's proprietary Prelude SkinPrep System, together with a noninvasive wireless biosensor and a wireless monitor or handheld device for needle-free, continuous monitoring of glucose levels.
The addressable market for needle-free, continuous wireless glucose monitoring in the hospital critical care setting exceeds $1 billion annually and the global glucose monitoring market exceeds $12 billion annually.
About Echo Therapeutics
Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2010, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
For More Information:Patrick T. Mooney, M.D.Chairman and Chief Executive Officer(508) 530-0329
Media: Richard SternStern &C o.(212) 888-0044
Connect With Us:- Visit our website at www.echotx.com- Follow us on Twitter at www.twitter.com/echotx- Join us on Facebook at www.facebook.com/echotx
SOURCE Echo Therapeutics, Inc.
GEYI-Alpha K.A.T system VS competitor JBII
One key advantage GEYI has over JBII is that the GEYI - Alphakat system has NO STACK (so no stack test).
http://www.scientificamerican.com/article.cfm?id=army-solid-waste-fuel-diesel-convert
http://postimage.org/image/1q5rysb44/
Dr.Christian Koch has more than 70 registered patents (National,European and World) referred to diverse fields:
-Preparation of diesel oil
-Diesel Oil from Waste by Catalytic depolymerization
-Preparation of high speed chambers
-Method and Device for Catalytic Oxidation
-High performance chamber mixer for catalytic oil suspensions
DOCKET NUMBER OF MAIN OWNED PATENTS
ALP6004WO
ALP6003WO
ALP6005WO
ALP6006N-WO
ALP6007N-WO
ALP6008WO
ALP7001BR
ALP7001CA
ALP7001CN
ALP7001IN
ALP7001JP
ALP7001RU
ALP7001US
ALP7002BR
ALP7002CA
ALP7002CN
ALP7002IN
ALP7002RU
ALP7002US
ALP7004BR
ALP7004CN
ALP7004IN
ALP7004RU
ALP7004US
ALP8001EP
ALP8002EP
ALP8004EP
ALP1001DE
ALP1002DE
ALP1003DE
ALP1004DE
ALP1005DE
ALP1006DE
ALP1007DE
ALP1008DE
ALP7003CN
ALP7003BR
ALP7003CA
ALP7003ID
ALP7003IN
ALP7003MY
ALP7003RU
ALP7003US
ALP7005KH
ALP8003EP
ALP8005EP
ALP8006EP
ALP8007EP
ALP8008EP
Covanta, Global Energy partner to test waste-to-diesel system; 50 percent lower capex potential compared to other waste-to-energy systems and a drop-in fuel
Jim Lane | March 6, 2009 | 2 Comments
In Massachusetts, Covanta will test Alphakat catalytic depolymerization technology for conversion of municipal solid waste the diesel fuel. Covanta is the largest US-based developer of waste-to-energy systems, but has previously focused on incineration of biomass for power generation. In this test, the company will use KDV 500 units from Germany at its SEMASS RDF facility, and expects to process 25-50 tons per day of municipal solid waste into 1 Mgy of diesel fuel.
The process will involve only limited increases in emissions compared to the existing process at the Covanta plant, and according to sources will have roughly half the capital cost of waste-to-ethanol systems, or around $2.50 in capex per gallon of fuel. The company said it may add an additional desulphurization module to the process to ensure meeting he EPA’s 15 ppm sulphur cap. The test is part of an extensive agreement signed with Global Energy, which has licensed the KDV technology for the United States.
Related Stories
* Enerkem, Edmonton, Alberta break ground on advanced energy facility in Canada
* Powers Energy of America readies for permitting process for $285 million waste-to-ethanol project
* Alpine Energy will use waste-to-energy system to produce 49 MW, steam for US Virgin Islands
* 2009 Waste to Fuels conference highlights available
* Edmonton waste-to-energy project expands with research center; project’s “tipping fee” structure revealed
If you enjoyed this article, subscribe to receive the Biofuels Digest email newsletter - the world's most widely read biofuels daily.
Your email:
Subscribe via RSS Feed Follow the Digest on Twitter Connect with us on LinkedIn
Comments (2)
Trackback URL | Comments RSS Feed
1.
Making Gas from Trash | Jesus Lives! says:
January 13, 2010 at 2:18 am
[...] • Army Hopes Trash-To-Diesel Project Can Lower War-Zone Risks, Costs – The New York Times • AlphaKat’s KDV Vision – AlphaKat • Covanta’s Energy From Waste 101 – Covanta • Covanta, Global Energy Partner to Test Waste-To-Diesel System – BioFuels Digest [...]
2.
Making Gas from Trash | Command the Raven says:
January 13, 2010 at 2:20 am
[...] • AlphaKat’s KDV Vision – AlphaKat • Covanta’s Energy From Waste 101 – Covanta • Covanta, Global Energy Partner to Test Waste-To-Diesel System – BioFuels Digest These icons link to social bookmarking sites where readers can share and discover new web [...]
« New Generation Biofuels completes $1.5 million private placement for expansion of new veggie-oil based biofuel
Ford backs ethanol industry’s drive towards E15 ethanol blends »
http://www.biofuelsdigest.com/blog2/2009/03/06/covanta-growth-energy-partner-to-test-waste-to-diesel-system-50-percent-lower-capex-potential-compared-to-other-waste-to-energy-systems-and-a-drop-in-fuel/
LOW TEMPERATURE PRESSURLESS HYDROGENATION
Preamble
As we know, hydrogenation and gasification are competitors since long time in the fuel production. Many combinations are developed for the hydrogenation with hydrogen and the gasification with air, oxygen and steam. In spite of the higher efficiency of the hydrogenation the gasification was more used than the hydrogenation.
The reason for was the high pressure of more than 90 bar for the hydrogenation with hydrogen gas and Nickel catalyst.
After the gasification showed many problems with sticky particles, dioxins and furans the competition with the hydrogenation is again discussed.
Discoveries in hydrogenation
Not expected was discovered a new way in the hydrogenation. When hydrogen in the reaction is substituted with biomass, than the necessary pressure for the reaction can be reduced from 90 bars to less than normal pressure. For this process we do not need nickel as the catalyst, we can use the much cheaper minerals of the biomass in form of cation-aluminium-silicate. Also the reaction temperature drops down to less than 300°C.
We have to take into account for this reaction the other energy input in the reaction. This reaction is not possible by heating from outside. This reaction takes place only by friction, by heating in a mixing chamber called as a friction turbine. Nobody heated a reaction by friction before. Nobody tried to heat a chemical reaction with a friction turbine. Therefore nobody before Alphakat could find this soft hydrogenation system.
Under the special condition of:
- Energy input in form a mixing chamber, called friction turbine
- Catalyst in the circulation medium for the system in form of cation-aluminium-silicate in the range of 5 to 20 %
We have a destruction of the biomass into a fuel molecule on the example of cellulose (1) and sugar (2) in form of
1. C6H11O5 = 2,5 CO2 + (CH2)n (3,5) + H (4)
2. C6H12O6 = 3 CO2 + (CH2)n (3) + H (6)
This 4 or 6 hydrogen (in stadium nascenti) hydrogenates the input material by normal pressure or under pressure all hydrocarbons including olefins, like plastic, oil, rubber and bitumen, to alkanes and substitute the catalyst in the reaction mass with hydrogen to realize such a low temperature of less than 300°C. This is a pure chemical reaction and has nothing to do with thermal splitting, pyrolysis or thermal destruction. Therefore the product is chemical with high quality, has no smell of pyrolysis and contains no ammonium, dioxins, furans and light components. Nobody went this way of the nature. All the crude oil is produced like this by lower temperature (14-19°C) and much
longer reaction time.
To get to know this reaction was not easy, because all the prejudgments of the chemical engineering show in the other direction. Only the consequences to continue looking for a 100 % dioxin free process lead the scientific activity to this process. Finally we found this reaction in a special mixing system with molecule fine powder of the cation-aluminium-silicate with addition lime in the reaction to hold the pH-value higher than 8,5. Than we found an unlimited life time of the catalyst.
Hydrogenation Test using Biomass
We discovered the process and the chemical structure in a special test series. A costumer wants to test residues from sun flower residue in the conversion to fuel. We tested several times 5 kg input and got 15 l diesel for each test. Therefore it was demonstrated, that the hydrogen of 5 kg press residue from sun flowers can hydrogenate 15 l waste oil to saturated hydrocarbons in the boiling range of 260°C. This is diesel. With other words, the hydrogen production of 1 kg biomass hydrogenates 3-4 kg mineral residues to diesel. In the case of coal we need another relation of biomass to coal with more biomass.
What is the efficiency of the biomass in mixing with other hydrocarbons?
- Hydrogenation of the oil and plastic to alkanes and
- Substitution of the catalyst for the CO2-extraction and depolimerization with hydrogen to make the product vaporizable, this means the chemical product diesel is not longer covered from catalyst and can evaporate in the product line.
Use of Catalyst
The catalyst which allows this reaction can be added to the process in the following way:
- We add cation-aluminium-silicate produced in the silicate ion of sodium-aluminate or
- We use biomass + lime for the production of diesel fuel and the ash is our catalyst we need for the industrial and municipal waste.
This molecule fine catalyst allows a new catalytic system:
- Not stored in a vessel in form of pellets or honeycomb,
- The catalyst is fine suspended in the circulation oil and goes to the input of Hydrocarbon to make the CO2-extraction and the depolimerization.
This is a new system with the opposite catalytic reaction, the catalyst coming to the input and not the reaction mass going to the catalyst. This is supported by the high friction in the friction turbine. This system of chemical conversion makes the high product quality of saturated hydrocarbons.
This is new and no other production system in the chemical industry uses the friction turbine for heating and reaction and uses the tanks only for the separation.
Technique improvements
In other words, up to now, on no other place of the technique of chemical plants is used the friction to heat and make the process. This is new in the technique and leads the fuel production in the direction of cheap catalytic hydrogenation with biomass and the minerals of the biomass as the catalyst.
When we compare the level of investment in the old processes with the new low pressure process with
- 90 bar hydrogen Nickel catalyst, higher temperature with heating from outside or
- under pressure, biomass as carrier for the hydrogen and heating with the friction turbine
we can realize that the low pressure hydrogenation with biomass is much cheaper than all the old processes of gasification, pyrolysis and high pressure hydrogenation with hydrogen gas.
The KDV process
This can be applied in the production of fuel, because the KDV-system is complete environmental friendly and the cheaper way to the hydrogenation. The efficiency is regarding to the low reaction temperature very high in the range of 70 - 91 %. All the dangerous materials, like chlorine, flour and molecule fine metals are absorbed by the lime with the high pH-value and the crystalline catalyst.
The hydrogen content of the biomass is about 20 %. This is going in the way of the hydrogenation and in the case of pure biomass in the way to the production water. This hydrogen is consumed in the mixing with technical production more for coal, transformer oil, PVC, Teflon, rubber, bitumen and refinery residue and less for plastic, waste oil and polymers like PE and PP.
All material, you can burn, you also can convert to diesel in the KDV
In summary we get the following results with the low hydrogenation process KDV:
- As long we have in the mixture enough biomass we get a unique product diesel with saturated hydrocarbons
- We do not need pressure
- The catalyst is coming from the biomass or synthetic from Alphakat and Partners
- We do not get any emission from the plant
- We use the vacuum system for inherent safety
- We do not form any poison hydrocarbons like Dioxins and Furans.
The KDV is therefore environmental friendly and has the highest efficiency from all known processes.
Yes and all the signals look to be pointing toward a favorable outcome for GEYI...
http://www.alphakat.de/temp/cooperation_program.php#
HomeAway Files for IPO Valued at as Much as $230 Million
By Nick Turner and Lee Spears - Mar 11, 2011 3:57 PM PT
HomeAway Inc., a vacation-rental website, filed to sell as much as $230 million worth of shares in an initial public offering, joining a resurgence in dot-com companies going public.
Morgan Stanley (MS) will lead the IPO, HomeAway said today in a regulatory filing. The company, which will trade under the ticker “AWAY,” also is working with Deutsche Bank AG (DBK), Goldman Sachs Group Inc. (GS) and JPMorgan Chase & Co. (JPM)
HomeAway, a six-year-old company based in Austin, Texas, runs the largest online marketplace for vacation rentals. The company, facing mounting competition from sites such as Airbnb Inc., says it may use some of the IPO proceeds to acquire businesses and add product lines. HomeAway’s IPO is larger than the pending deals of two other Internet companies: LinkedIn Corp. and Pandora Media Inc.
“This is certainly one of the larger venture-backed IPOs to have filed in quite some time,” said Lise Buyer, principal of Class V Group, an IPO advisory firm in Palo Alto, California. “There’s clearly an appetite in the marketplace for solid new growth stories.”
HomeAway’s sales climbed 40 percent to $167.9 million last year, according to the filing. That helped the company narrow its net loss to $18.3 million, or 48 cents a share, from $25.8 million, or 70 cents, in 2009.
Rental Listings
HomeAway has more than 540,000 rental listings in 120 countries, according to its website. Homeowners pay an annual fee of about $300 to list, and the site is free for renters. In addition to HomeAway.com, the company runs Vacation Rentals by Owner, or VRBO.com, and VacationRentals.com.
HomeAway raised about $500 million in private capital from Austin Ventures, also based in Austin, and Redpoint Ventures in Menlo Park, California, which first invested in HomeAway in 2005. Redpoint, along with Palo Alto, California-based Technology Crossover Ventures and Institutional Venture Partners, invested $250 million in 2008.
Last year, HomeAway bought Escapia Inc. and Instant Software Inc., providers of software for vacation rentals, which together represent almost 1,700 property-management customers, HomeAway said in October.
The IPO is likely to happen by June, two people familiar with the matter said last month. Pandora, an Internet-radio company, announced plans in February to raise $100 million in an IPO. LinkedIn, a business networking site, filed for an IPO in January that would raise as much as $175 million.
To contact the reporters on this story: Nick Turner in San Francisco at nturner7@bloomberg.net; Lee Spears in New York at lspears3@bloomberg.net
To contact the editor responsible for this story: Thomas Giles at tgiles5@bloomberg.net
"Pluristem has found its PLX cells to be cytoprotective, which the company believes play a role in protecting bone marrow cells from the adverse effects of radiation exposure." ...
I found this to be extremely interesting and while it may grab some headline attention due to the potentially tragic implications from the Japan disaster, the ability to help patients that are undergoing radiation treatment is what I see at the the really big news.
Mesoblast Limited (ASX:MSB) (PINK:MBLTY) wishes to inform the market that the Board of its strategic partner Cephalon Inc. (NASDAQ:CEPH) has rejected the unsolicited proposal from Valeant Pharmaceuticals International Inc (NYSE:VRX) to acquire its issued share capital or certain assets.
Melbourne, April 7, 2011 (ABN Newswire) -
The full Cephalon response can be viewed at: http://www.cephalon.com/media/news-releases.html
Reflecting on the value of its pipeline, the Cephalon Board said it "has created one of the broadest pipelines in the industry, with 10 late-stage product candidates targeted at novel and 'best-in-class' therapeutics. This includes six indications with blockbuster potential which are projected to begin launching in the next three years."
About Mesoblast Limited
Mesoblast Limited (ASX:MSB) (PINK:MBLTY) is a world leader in commercializing biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.com
Contact
Julie Meldrum
Corporate Communications Director
T: +61-3-9639-6036
C: +61-419-228-128
Email:julie.meldrum@mesoblast.com
Link: http://www.abnnewswire.net/media/en/docs/353086.pdf
BIOLASE Technology To Raise Approximately $1.80 M From Institutional Investors At $5.60 Per Shr
Last update: 4/8/2011 10:12:01 AM
(MORE TO FOLLOW) Dow Jones Newswires (212-416-2400)
April 08, 2011 10:12 ET (14:12 GMT)
Market Report Analyzes Nanotechnology-based Printing Segment
By Cameron Chai
MarketResearch.com has declared that it has added the MarketsandMarkets report titled, ‘Global Printed Electronics Market: Materials, Manufacturing Technologies, Applications & Trends’, to its Components market report portfolio.
The report describes the advantages of using printed electronics technology including low production cost and choice of multiple substrates that are governing the international printed electronics market. The report states that this market segment will grow from $2.8 billion recorded in 2008 to an estimated $24.25 billion in 2015, at a CAGR of 38.4% for the period 2010 to 2015.
Screen printing captures most of the market since it is used to develop sensors, RFID, and displays. Printed displays dominate the application market, while printed photovoltaic (PV) dominates because the demand for alternative energy sources is also growing. This market is estimated to grow from $0.23 billion in 2008 to $3.93 billion by 2015 at a CAGR of 52.1% for the period 2010 to 2015.
The report has also addressed issues such as high growth market segments, forecasts, opportunities, Key players and their chosen fields, and market trends and strategies.
Source: http://www.marketresearch.com/
Posted April 8th, 2011
Is ARM Holdings the Perfect Stock?
http://www.fool.com/investing/high-growth/2011/04/07/is-arm-holdings-the-perfect-stock.aspx
Dan Caplinger
April 7, 2011
Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?
One thing's for sure: You'll never discover truly great investments unless you actively look for them. Let's discuss the ideal qualities of a perfect stock, then decide if ARM Holdings (Nasdaq: ARMH ) fits the bill.
The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:
* Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
* Margins. Higher sales mean nothing if a company can't produce profits from them. Strong margins ensure that company can turn revenue into profit.
* Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
* Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.
* Valuation. You can't afford to pay too much for even the best companies. By using normalized figures, you can see how a stock's simple earnings multiple fits into a longer-term context.
* Dividends. For tangible proof of profits, a check to shareholders every three months can't be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.
With those factors in mind, let's take a closer look at ARM Holdings.
Factor
What We Want to See
Actual
Pass or Fail?
Growth 5-year annual revenue growth > 15% 11.8% Fail
1-year revenue growth > 12% 33.3% Pass
Margins Gross margin > 35% 93.6% Pass
Net margin > 15% 21.1% Pass
Balance sheet Debt to equity < 50% 0% Pass
Current ratio > 1.3 2.42 Pass
Opportunities Return on equity > 15% 10.5% Fail
Valuation Normalized P/E < 20 115.62 Fail
Dividends Current yield > 2% 0.5% Fail
5-year dividend growth > 10% 28.1% Pass
Total Score 6 out of 10
Source: Capital IQ, a division of Standard & Poor's. Total score = number of passes.
ARM Holdings scores a very respectable score of six. Its future, however, could become a lot brighter as the company makes big waves in a business dominated by some of the world's largest companies.
For years, two players have dominated the PC industry: Microsoft with its operating system software, and Intel (Nasdaq: INTC ) with its processors. With their chokehold over the computers that most people used, those two companies made life hard for also-rans such as Advanced Micro Devices (NYSE: AMD ) , which was relegated to making processors that piggybacked off Intel's instruction set, and other companies were unable to crack the processor market.
But recently, Microsoft announced that it's building a version of Windows that runs on platforms used by ARM Holdings' processors. As a result, ARM Holdings is challenging Intel not just for mobile devices but also in Intel's core PC market.
Meanwhile, the company has made serio us inroads in the booming mobile industry. ARM has made licensing deals with Broadcom (Nasdaq: BRCM ) to pair up on chipsets for low-cost smartphones for the global market, as well as seeking a place in higher-end devices from Apple (Nasdaq: AAPL ) and licensing deals to a group of major chip companies that includes stalwarts such as Texas Instruments (NYSE: TXN ) . Moreover, it has a vital partnership with IBM (NYSE: IBM ) helping ARM keep up with the latest technological innovations.
At more than 100 times normalized earnings, ARM isn't cheap. But if the company can stay on its current growth path, its financial performance could easily justify its current valuation. If you're willing to make a speculative play, ARM Holdings may be the perfect stock to do it with.
Keep searching
No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate the best investments from the rest.
Finding the perfect stock is only one piece of a successful investment strategy. Get the big picture by taking a look at our 13 Steps to Investing Foolishly.
Legal Information. © 1995-2011 The Motley Fool. All rights reserved.
http://www.fool.com/investing/high-growth/2011/04/07/is-arm-holdings-the-perfect-stock.aspx
BIOLASE to Adopt Direct and Multi-Distributor Sales Model in Germany
Biolase (NASDAQ:BLTI)
Today : Thursday 7 April 2011
BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental laser manufacturer and distributor, announced today plans to immediately expand BIOLASE Europe, GmbH to now include a direct sales force, along with service and support operations, for the German market. The increased operations will support the rapid growth of dental lasers in emerging markets in Eastern Europe and the Middle East. Located in Floss, Germany, which is centrally located approximately halfway between Munich and Prague, the existing 16,000 sq. ft. facility is entirely owned by the Company and is fully certified to manufacture and service all models of BIOLASE's lasers.
CEO Federico Pignatelli said, "Unfortunately, our sales of all-tissue lasers in Germany and several other countries under exclusive distribution arrangements have lagged other countries in Europe and were below our goals. After a thorough review, we have chosen to adopt the same type of direct and multi-distributor sales model in Germany that we recently successfully implemented in North America in September 2010. This model rapidly returned our North American operations to strong sales growth and renewed profitability. And, we expect the same to happen in Germany, historically a strong market for BIOLASE where we already have approximately 300 owners of our all-tissues lasers."
"Germany is the World's third largest dental laser market with over 52,000 dentists, equal to one-third of the U.S. dental market," Pignatelli added. "It is the largest economy in Western Europe and is among the highest revenue-per-dental practice in the World. Our expectations are high for such a mature and promising high technology dental market."
Pignatelli also commented on BIOLASE's recent successes at the International Dental Show (IDS) in Cologne, Germany. "The introduction of our new flagship all-tissue laser system, the WaterLase® iPlus™, to the international dental community at the IDS in March exceeded all of our expectations. The positive response to its design, greatly enhanced performance and innovative features was shared by new and existing BIOLASE customers, laser luminaries, and attendees, as well as current and prospective international distributors."
"Our booth was packed from start to finish and our distributor meeting at the show was the largest and most enthusiastic in Company history," Pignatelli added. "The international order rate for the iPlus and our wireless iLase™ five watt diode laser has temporarily exceeded our production capacity but, thankfully, we were able to ship units on a priority basis to dealers in key markets for their spring trade shows to continue the launch throughout the World."
France, Spain, Italy, England, the Netherlands, Austria, Belgium, Australia and New Zealand also will become non-exclusive distributor territories pending satisfactory performance discussions on an individual country-by-country basis. BIOLASE will continue to sell through its current distribution channels in all other international markets.
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the World's leading Dental Laser company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment, products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. Other products under development address ophthalmology and other medical and consumer markets.
For updates and information on laser and Waterlase dentistry, find BIOLASE at http://www.biolase.com, Twitter at http://twitter.com/GoWaterlase, and YouTube at http://www.youtube.com/user/Rossca08.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
For further information, please contact:
Jill Bertotti
Allen & Caron
+1-949-474-4300
Well this is disappointing. I don't like restatements or auditor changes. I plan to cut my losses here and I hope it goes well for those that hold. Closed at $.66 but I expect a gap down tomorrow :(
Win some and lose some. Glad I'm not in too deep on this one. My batting average has been quite good this year so far so I can't complain.
And then NNVC went Plaid - :)
Lightspeed is too slow.
"What's a matter Colonel Sanders - chicken?" lol
It is interesting to watch complaints after two decent up days in a row.
Thanks Doc FG for all the work you do here.
Nice Progress - almost a double in just over a year.
Looks like the stage is set with timing getting close and I don't like to chase on a stock this thin so I have built a core position and plan to hold until the deal is done. JMHO
Touched a new 52 week high today $6.03
BIOLASE Announces That It Expects Revenues for First Quarter to Exceed Previous Guidance
Biolase (NASDAQ:BLTI)
Intraday Stock Chart
Today : Wednesday 6 April 2011
BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser manufacturer and distributor, announced today that, based on a preliminary review of its financial performance, the Company expects to report net revenue of approximately $10.4 million for the first quarter ended March 31, 2011. This is an increase of approximately 10 percent from the updated guidance provided last month in the mid-range of $9.5 million ($9.25 million to $9.75 million) and an increase of approximately 136 percent from $4.4 million of net revenue for the first quarter ended March 31, 2010.
Federico Pignatelli, Chairman and CEO, said, "We are pleased with the better than expected revenues that we believe we have achieved during the first quarter, traditionally our slowest quarter of the year. Our recently expanded direct sales force in North America and several of our international distributors have contributed to the growing sales traction in the period and a strong initial demand for our new flagship all-tissue laser system launched in January, the WaterLase® iPlus™, have all contributed to the quarter performance. Orders for the WaterLase iPlus have exceeded our expectations, and we are working diligently to manufacture enough to keep up with the current demand. The launch of the Waterlase iPlus is shaping up to become the most successful in the history of the Company and we believe it will be a strong contributor to our future revenue growth. Demand for our wireless iLase™ five watt diode laser system also remained strong in the period as we continued to receive new orders and work through our existing backlog."
The Company will provide additional details on a quarterly conference call and webcast when it reports full financial results in May.
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the World's leading Dental Laser company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment, products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. Other products under development address ophthalmology and other medical and consumer markets.
For updates and information on laser and Waterlase dentistry, find BIOLASE at http://www.biolase.com, Twitter at http://twitter.com/GoWaterlase, and YouTube at http://www.youtube.com/user/Rossca08.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
For further information, please contact:
Jill Bertotti
Allen & Caron
+1-949-474-4300